These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16224157)

  • 1. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.
    Kim KM; Choi WB; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Korean Med Sci; 2005 Oct; 20(5):821-8. PubMed ID: 16224157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease].
    Moon W; Choi MS; Moon YM; Paik SW; Lee JH; Koh KC; Yoo BC; Rhee JC; Shim SG
    Korean J Hepatol; 2005 Jun; 11(2):125-34. PubMed ID: 15980671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
    Peng H; Liu J; Yang M; Tong S; Yin W; Tang H; Hu P; Hu H; Ren H
    J Clin Pharmacol; 2014 Feb; 54(2):189-200. PubMed ID: 24105676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
    Peters MG; Hann Hw Hw; Martin P; Heathcote EJ; Buggisch P; Rubin R; Bourliere M; Kowdley K; Trepo C; Gray Df Df; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart CL
    Gastroenterology; 2004 Jan; 126(1):91-101. PubMed ID: 14699491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B.
    He Z; Wang J; Liu K; Huang H; Du Y; Lin Z; Cai M; Feng X
    Clin Res Hepatol Gastroenterol; 2012 Dec; 36(6):592-7. PubMed ID: 23069315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.
    Schiff ER; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann HL; Samuel D; Zeuzem S; Lilly L; Rendina M; Villeneuve JP; Lama N; James C; Wulfsohn MS; Namini H; Westland C; Xiong S; Choy GS; Van Doren S; Fry J; Brosgart CL;
    Hepatology; 2003 Dec; 38(6):1419-27. PubMed ID: 14647053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis.
    Lv GC; Yao JM; Yang YD; Zheng L; Sheng JF; Chen Y; Li LJ
    World J Gastroenterol; 2013 Jun; 19(22):3481-6. PubMed ID: 23801842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil: a review of its use in chronic hepatitis B.
    Dando T; Plosker G
    Drugs; 2003; 63(20):2215-34. PubMed ID: 14498759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
    Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
    Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
    J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection.
    Kim DY; Kim HJ; Lee CK; Suh JH; Kim DH; Cho YS; Won SY; Park BK; Park IS
    Liver Int; 2007 Feb; 27(1):47-53. PubMed ID: 17241380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Yang Q; Gong ZJ; Hu DF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.
    Schiff E; Lai CL; Hadziyannis S; Neuhaus P; Terrault N; Colombo M; Tillmann H; Samuel D; Zeuzem S; Villeneuve JP; Arterburn S; Borroto-Esoda K; Brosgart C; Chuck S;
    Liver Transpl; 2007 Mar; 13(3):349-60. PubMed ID: 17326221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
    Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
    Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
    N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B.
    Vassiliadis T; Nikolaidis N; Giouleme O; Tziomalos K; Grammatikos N; Patsiaoura K; Zezos P; Gkisakis D; Theodoropoulos K; Katsinelos P; Orfanou-Koumerkeridou E; Eugenidis N
    Aliment Pharmacol Ther; 2005 Mar; 21(5):531-7. PubMed ID: 15740536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of combination therapy of lamivudine and adefovir dipivoxyl for patients with hepatitis B-induced decompensated liver cirrhosis].
    Yang J; Zhu X; Wang H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Dec; 37(12):1269-73. PubMed ID: 23281382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.